Expert Discusses Real-World Data for Regorafenib in mCRC

Real-world dosing data for regorafenib (Stivarga) in patients with metastatic colorectal cancer (mCRC) was presented at the 2018 ESMO Congress from the prospective, observational CORRELATE study. According to Juan Manuel O’Connor, MD, incorporating real-world data has become increasingly important in daily use of anticancer agents.¹

A dose of regorafenib at 160 mg daily for a 3-week-on/1-week-off schedule is currently indicated for the treatment of refractory patients with mCRC. The real-world data from CORRELATE reported on regorafenib in patients across 13 countries in Europe, Latin America, and Asia. The principal aim of this study was to assess safety.

Findings showed that 57% of the 1037 patients evaluated started treatment at 160 mg, 30% of patients began at 120 mg, and 13% began at ≤80 mg. Investigators noted that dose reductions were most frequent in the 160-mg group, and treatment modifications were due mostly to treatment-emergent adverse events (TEAEs; 66%).

Grade ≥3 TEAEs occurred in 62% of patients, 36% of which were attributed to regorafenib. The most common of the grade ≥3 TEAEs related to regorafenib were fatigue (9%), hand-foot skin reaction (7%), and hypertension (6%). Although grade 5 TEAEs were observed in 17% of patients, only 1% were deemed to be regorafenib related.

The safety profile of regorafenib has led to studies evaluating dose escalation as a way to limit TEAEs. Most recently, the NCCN revised its guidelines regarding regorafenib, based on findings from the ReDOS study.²

In ReDOS, investigators evaluated a dose-escalation strategy of regorafenib beginning at 80 mg and ending at 160 mg for previously treated patients with mCRC. Positive overall survival (OS) and progression-free survival (PFS) data led to the recommendation of a starting dose of 80 mg/daily on days 1 to 7, escalating to 120 mg/daily on days 8 to 14, and concluding with 160 mg/daily on days 15 to 21. From there, subsequent cycles should use 160 mg of regorafenib on days 1 to 21 every 28 days, according to the NCCN.

In an interview withTargeted Oncology, O'Connor, head, Department Gastrointestinal Oncology, Department of Clinical Oncology, Institute Alexander Fleming, Buenos Aires, discussed the final results of the CORRELATE regorafenib study in patients with mCRC, emphasizing the importance of real-world data.

TARGETED ONCOLOGY:Could you please share the final results from CORRELATE?O’Connor:The approval dose of regorafenib for the treatment of patients with mCRC is 160 mg. There are some differences between the real-world setting and the patients included in the randomized clinical trial. The aim of our study was to look at the data from the real-world setting of refractory mCRC in more detail.

The final results of our study described a starting dose in patients based on the decisions of the treating physicians. Of the patients enrolled on the study, 57% of those who started at the recommended dose of 160 mg, 30% at 120 mg, and 13% at 80 mg. That is very important information.

TARGETED ONCOLOGY:What are your thoughts on regorafenib in a dose-escalation regimen?O’Connor:There were very important data from the ReDOS trial based on the escalation and re-escalation. In our study, around 20% of our patients required an escalated dose. We plan to analyze this subgroup based on the new data coming from the ReDOS trial.

The primary objective of our study was to characterize the use of regorafenib in a real-world setting based on safety and efficacy, mainly in terms of progression-free and overall survival. Based on the observational study, safety is a very important issue to keep in mind.

TARGETED ONCOLOGY:Can you speak to the tolerability of regorafenib?O’Connor:One of the problems with the use of regorafenib is the starting dose. Therefore, in the real-world observational study, the data were not equal in terms of safety. There are many doctors that used a starting dose that was different than the recommended dose. It is important to keep the ReDOS data in mind with this study. These are important data because we have more data from the treating physician perspective, as they feel more confident in the dosing when treating patients with refractory mCRC.

TARGETED ONCOLOGY:What would be your take-home message about CORRELATE?

O’Connor:Our take-home message from this observational study was that, despite the flexible doses of regorafenib, there was no impact in the effectiveness in terms of the median OS and median PFS. It was 7.7 months in terms of median OS, which was a little bit more than the 2 previous trials—CORRECT and CONCUR. The median PFS was 2.9 months.

In the future, it is important to consider data from the real-world setting. There is likely a big difference between the patients included in the randomized clinical trial compared with the real world. We will get more information from routine clinical practice, mainly in terms of safety.

References:

1. O'Connor JM, Ducreux M, Petersen LN, et al. Real-world dosing of regorafenib (REG) in metastatic colorectal cancer (mCRC): final results from the prospective, observational CORRELATE study.Ann Oncol.2018;29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281
2. Bekaii-Saab TS, Ou FS, Anderson DM, et al. Regorafenib dose optimization study (ReDOS): Randomized phase II trial to evaluate dosing strategies for regorafenib in refractory metastatic colorectal cancer (mCRC)—an ACCRU Network study.J Clin Oncol.2018;36(suppl 4S; abstr 611).